Meningitis: Vaccination

Department of Health written question – answered on 11th March 2015.

Alert me about debates like this

Photo of Tony Cunningham Tony Cunningham Labour, Workington

To ask the Secretary of State for Health, what discussions his Department has had with Novartis during price negotiations on the meningitis B vaccine on risk sharing in the development and implementation of that vaccine.

Photo of Jane Ellison Jane Ellison The Parliamentary Under-Secretary of State for Health

The meningitis B (MenB) vaccine has already been developed by Novartis. Implementation of the MenB programme is dependent on the vaccine being obtained at a cost effective price as recommended by the Joint Committee on Vaccination and Immunisation.

The Department is continuing to negotiate with the manufacturer and the content of these negotiations is confidential. GlaxoSmithKline (GSK) completed its purchase of Novartis’s non-influenza vaccine business on 2 March 2015 and therefore, further negotiations are continuing with GSK.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.